BBT-176

BBT-176 is a novel, orally bioavailable, fourth-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) developed to target EGFR mutations associated with resistance to earlier-generation EGFR TKIs in non-small cell lung cancer (NSCLC), particularly the C797S mutation and triple-mutant forms such as L858R/T790M/C797S and 19Del/T790M/C797S. It demonstrates potent inhibitory activity against these resistant EGFR mutants both in vitro and in vivo, including patient-derived xenograft models. Early clinical data show tumor shrinkage in patients with advanced NSCLC harboring these mutations who have progressed on prior EGFR TKI therapy. The drug is being evaluated as monotherapy and in combination with cetuximab[2][3][5][6].